502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium

Chen, T.W-W.; Pang, Angela; Puhaindran, Mark E.; Maw, Myo; Loong, Herbert H.; Sriuranpong, Virote; Cc, Chang; Teo, Sharon; Mingmalairak, Siyamol; Hirose, Takeshi; Kawai, Akira; Farid, Mohamad; Tan, Sze Huey; Goh, Wei Lin; Quek, Richard; Chan, Jeffrey; Leung, A. K. C.; Ngan, Roger K.C.

doi:10.1093/annonc/mdw597.002

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of angiosarcoma locations has been reported slightly differently in previous literature. The frequency of primary tumor locations in this study was similar to that of the studies from Asian countries [1, 9] but different to that of Western countries, where there are less frequent cases of liver (range 1.8%–6.0%) angiosarcomas but more frequently extremities-located angiosarcomas (range 15.3%–52.0%) [2, 3].…”

supporting

confidence: 85%

“…In the present study, even though the median PFS and OS of patients who were treated with curative surgery and adjuvant CT were numerically the longest, the efficacy of adjuvant CT was still questionable due to potential bias from the small sample size and heterogenous primary tumor locations. In a palliative setting, Chen et al [9] demonstrated that patients who received palliative CT demonstrated longer OS than those who did not receive it. Similarly, in our study, we have found that patients who received palliative CT had better prognosis, including PFS and OS than those with best supportive care.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes of angiosarcoma: a single institution experience

Kim

Seo

Kim

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

supporting

confidence: 85%

mentioning

confidence: 99%

Clinical outcomes of angiosarcoma: a single institution experience

Kim

Seo

Kim

et al. 2019

Cancer Communications

View full text Add to dashboard Cite

“…Preliminary sessions aimed at setting the knowledge base for each selected topic b. Handled by an assigned faculty from the ASC c. 30-40-minute presentations followed by [5][6][7][8][9][10] minutes for open forum d. Prior to the start of all activities, all participants completed a 20-item MCQ pre-test.…”

Section: Educational Activities Utilizedmentioning

confidence: 99%

“…This collaborative effort has proven to be very successful, with the ASC presenting its first research output on Angiosarcoma at the ESMO Asia Conference in December 2016. This consists of 2 projects on Angiosarcoma 7,8 , both of which were presented in paper presentation sessions and were well-received.…”

Section: Introductionmentioning

confidence: 99%

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

2022

Acta Med Philipp

View full text Add to dashboard Cite

Background. Sarcomas, a heterogenous group of malignancies consisting of tumors, are rarely encountered in most general oncology clinics. As a result, most general oncologists have very little experience in dealing with these tumors and resulting in poorer treatment and survival outcomes. Having successful collaborative efforts in research, the Asian Sarcoma Consortium (ASC) pioneered a Sarcoma Preceptorship Program with its main goal of increasing awareness of the multidisciplinary approach in the management of sarcomas.Objective. The objective of this study is to evaluate the ASC Sarcoma Preceptorship Program using the first 2 levels of the Kirkpatrick Evaluation Model: Level 1) Reaction -through using satisfaction surveys; and Level 2) Knowledge -focusing on the amount of information gained from the activity evaluated by test-retest method.Methods. The 2-day preceptorship program held in Singapore utilized educational activities such as didactic lectures, multidisciplinary case discussions, and case presentations. The program was evaluated using: 1) pre-test and posttest; 2) satisfaction survey from ASC; and 3) satisfaction survey made by the sponsor, Novartis Pharma.Results. The preceptorship program enrolled 30 participants, most from the Asia-Pacific region. The overall results from the satisfaction surveys were generally optimistic, with results showing high levels of satisfaction with regard to the time allotment, scope of topics, and how helpful each session was. Test results showed that participants scored lower in post-test as compared to the pre-test. Computation of the Coefficient of Test reliability showed that although the pre-test was highly reliable, this was not true of the post-test. Conclusions.Based on the Level 1 evaluation, the program was successful in terms of both participant and faculty satisfaction. However, certain areas for improvement were identified and recommendations were made in order to effect improvements for future iterations of this preceptorship.

show abstract

“…In another retrospective study from the Asia Sarcoma Consortium, the median PFS of liposomal doxorubicin in first-line advanced AS was 2.8 months. However, the efficacy in terms of PFS was not significantly different from advanced AS patients treated with single-agent paclitaxel [ 34 ].…”

Section: Advanced Angiosarcomamentioning

confidence: 99%

Optimal Clinical Management and the Molecular Biology of Angiosarcomas

Chen

Burns

Jones

et al. 2020

Cancers

View full text Add to dashboard Cite

Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. Surgery remains the standard treatment for localized angiosarcoma but neoadjuvant systemic treatment may improve the curability. For advanced angiosarcoma, anthracyclines and taxanes are the main chemotherapy options. Anti-angiogenic agents have a substantial role but the failure of a randomized phase 3 trial of pazopanib with or without an anti-endoglin antibody brings a challenge to future trials in angiosarcomas. Immune checkpoint inhibitors as single agents or in combination with oncolytic virus may play an important role but the optimal duration remains to be investigated. We also report the current understanding of the molecular pathways involved in angiosarcoma pathogenesis including MYC amplification, activation of angiogenic pathways and different molecular alterations that are associated with angiosarcomas of different aetiology. The success of the patient-partnered Angiosarcoma Project (ASCProject) has provided not only detailed insights into the molecular features of angiosarcomas of different origins but also offers a template for future fruitful collaborations between patients, physicians, and researchers. Lastly, we provide our perspective of future developments in optimizing the clinical management of angiosarcomas.

show abstract

502O_PR Optimal first line systemic therapy in patients (pts) with metastatic angiosarcoma: A report from the Asian Sarcoma Consortium

Cited by 4 publications

References 0 publications

Clinical outcomes of angiosarcoma: a single institution experience

Clinical outcomes of angiosarcoma: a single institution experience

The Asian Sarcoma Consortium Sarcoma Preceptorship Program: A Program Evaluation Study Utilizing the Kirkpatrick Model (Level 1 and 2)

Optimal Clinical Management and the Molecular Biology of Angiosarcomas

Contact Info

Product

Resources

About